Treatment of postnasal drip with proton pump inhibitors: A prospective, randomized, placebo-controlled study

Sachin Pawar, Hyun J. Lim, Matthew Gill, Timothy Smith, Albert Merati, Robert J. Toohill, Todd A. Loehrl

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Patients commonly present with complaints of postnasal drainage (PND) without objective evidence to support a sinonasal or infectious etiology. PND has been attributed to extra-esophageal reflux (EER), and an empiric trial of antireflux medication often is used to treat PND and associated symptoms. This study was performed to (1) evaluate the relationship between symptoms of EER and PND and (2) assess the efficacy of proton pump inhibitors (PPIs) in the management of PND. Methods: Patients with a chief complaint of PND without objective evidence of sinonasal inflammatory disease were enrolled in a prospective, double-blinded, randomized placebo-controlled trial using rabeprazole, 20 mg, orally twice daily or placebo for 90 days. Subjects completed two-site 24-hour pharyngeal pH probe monitoring before treatment. Outcome measures included pre- and posttreatment visual analog scales for PND symptoms, reflux symptom index, and reflux finding score (RFS). Results: Forty-seven patients were enrolled (mean age, 55 years) - 21 patients in the PPI group and 26 in the placebo group. Fifty-six percent of subjects had pH probe confirmed EER using a cutoff of pH <5.0. Baseline symptom measures between subjects with and without EER were not different. Compared with placebo, subjects receiving rabeprazole reported significant reduction in PND frequency (p = 0.0180), hoarseness (p = 0.0164), and chronic cough (p = 0.0204). The RFS decreased slightly in the placebo group (p = 0.1490) whereas it increased slightly in the PPI group (p = 0.5235). This difference between groups was significant (p = 0.0272). Conclusion: Although 50% of subjects had evidence of EER, there was no difference in baseline symptoms between subjects with and without. Our findings support the potential benefit of PPI therapy for reducing PND frequency, hoarseness, and chronic cough, and confirm a placebo effect for other laryngopharyngeal reflux symptoms. The effect on laryngeal findings is mixed and patients may experience symptomatic improvement before changes in laryngoscopic appearance.

Original languageEnglish (US)
Pages (from-to)695-701
Number of pages7
JournalAmerican Journal of Rhinology
Volume21
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Proton Pump Inhibitors
Drainage
Placebos
Gastroesophageal Reflux
Rabeprazole
Hoarseness
Therapeutics
Cough
Laryngopharyngeal Reflux
Placebo Effect
Visual Analog Scale
Randomized Controlled Trials
Outcome Assessment (Health Care)

Keywords

  • Extra-esophageal reflux
  • Gastro-esophageal reflux
  • Pepsin
  • Postnasal drip
  • Proton pump inhibitors
  • Reflux
  • Reflux finding score
  • Reflux symptom index

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Treatment of postnasal drip with proton pump inhibitors : A prospective, randomized, placebo-controlled study. / Pawar, Sachin; Lim, Hyun J.; Gill, Matthew; Smith, Timothy; Merati, Albert; Toohill, Robert J.; Loehrl, Todd A.

In: American Journal of Rhinology, Vol. 21, No. 6, 11.2007, p. 695-701.

Research output: Contribution to journalArticle

Pawar, Sachin ; Lim, Hyun J. ; Gill, Matthew ; Smith, Timothy ; Merati, Albert ; Toohill, Robert J. ; Loehrl, Todd A. / Treatment of postnasal drip with proton pump inhibitors : A prospective, randomized, placebo-controlled study. In: American Journal of Rhinology. 2007 ; Vol. 21, No. 6. pp. 695-701.
@article{ffbcc831de3849668b2af2e0d2f992c6,
title = "Treatment of postnasal drip with proton pump inhibitors: A prospective, randomized, placebo-controlled study",
abstract = "Background: Patients commonly present with complaints of postnasal drainage (PND) without objective evidence to support a sinonasal or infectious etiology. PND has been attributed to extra-esophageal reflux (EER), and an empiric trial of antireflux medication often is used to treat PND and associated symptoms. This study was performed to (1) evaluate the relationship between symptoms of EER and PND and (2) assess the efficacy of proton pump inhibitors (PPIs) in the management of PND. Methods: Patients with a chief complaint of PND without objective evidence of sinonasal inflammatory disease were enrolled in a prospective, double-blinded, randomized placebo-controlled trial using rabeprazole, 20 mg, orally twice daily or placebo for 90 days. Subjects completed two-site 24-hour pharyngeal pH probe monitoring before treatment. Outcome measures included pre- and posttreatment visual analog scales for PND symptoms, reflux symptom index, and reflux finding score (RFS). Results: Forty-seven patients were enrolled (mean age, 55 years) - 21 patients in the PPI group and 26 in the placebo group. Fifty-six percent of subjects had pH probe confirmed EER using a cutoff of pH <5.0. Baseline symptom measures between subjects with and without EER were not different. Compared with placebo, subjects receiving rabeprazole reported significant reduction in PND frequency (p = 0.0180), hoarseness (p = 0.0164), and chronic cough (p = 0.0204). The RFS decreased slightly in the placebo group (p = 0.1490) whereas it increased slightly in the PPI group (p = 0.5235). This difference between groups was significant (p = 0.0272). Conclusion: Although 50{\%} of subjects had evidence of EER, there was no difference in baseline symptoms between subjects with and without. Our findings support the potential benefit of PPI therapy for reducing PND frequency, hoarseness, and chronic cough, and confirm a placebo effect for other laryngopharyngeal reflux symptoms. The effect on laryngeal findings is mixed and patients may experience symptomatic improvement before changes in laryngoscopic appearance.",
keywords = "Extra-esophageal reflux, Gastro-esophageal reflux, Pepsin, Postnasal drip, Proton pump inhibitors, Reflux, Reflux finding score, Reflux symptom index",
author = "Sachin Pawar and Lim, {Hyun J.} and Matthew Gill and Timothy Smith and Albert Merati and Toohill, {Robert J.} and Loehrl, {Todd A.}",
year = "2007",
month = "11",
doi = "10.2500/ajr.2007.21.3098",
language = "English (US)",
volume = "21",
pages = "695--701",
journal = "American Journal of Rhinology and Allergy",
issn = "1945-8924",
publisher = "OceanSide Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Treatment of postnasal drip with proton pump inhibitors

T2 - A prospective, randomized, placebo-controlled study

AU - Pawar, Sachin

AU - Lim, Hyun J.

AU - Gill, Matthew

AU - Smith, Timothy

AU - Merati, Albert

AU - Toohill, Robert J.

AU - Loehrl, Todd A.

PY - 2007/11

Y1 - 2007/11

N2 - Background: Patients commonly present with complaints of postnasal drainage (PND) without objective evidence to support a sinonasal or infectious etiology. PND has been attributed to extra-esophageal reflux (EER), and an empiric trial of antireflux medication often is used to treat PND and associated symptoms. This study was performed to (1) evaluate the relationship between symptoms of EER and PND and (2) assess the efficacy of proton pump inhibitors (PPIs) in the management of PND. Methods: Patients with a chief complaint of PND without objective evidence of sinonasal inflammatory disease were enrolled in a prospective, double-blinded, randomized placebo-controlled trial using rabeprazole, 20 mg, orally twice daily or placebo for 90 days. Subjects completed two-site 24-hour pharyngeal pH probe monitoring before treatment. Outcome measures included pre- and posttreatment visual analog scales for PND symptoms, reflux symptom index, and reflux finding score (RFS). Results: Forty-seven patients were enrolled (mean age, 55 years) - 21 patients in the PPI group and 26 in the placebo group. Fifty-six percent of subjects had pH probe confirmed EER using a cutoff of pH <5.0. Baseline symptom measures between subjects with and without EER were not different. Compared with placebo, subjects receiving rabeprazole reported significant reduction in PND frequency (p = 0.0180), hoarseness (p = 0.0164), and chronic cough (p = 0.0204). The RFS decreased slightly in the placebo group (p = 0.1490) whereas it increased slightly in the PPI group (p = 0.5235). This difference between groups was significant (p = 0.0272). Conclusion: Although 50% of subjects had evidence of EER, there was no difference in baseline symptoms between subjects with and without. Our findings support the potential benefit of PPI therapy for reducing PND frequency, hoarseness, and chronic cough, and confirm a placebo effect for other laryngopharyngeal reflux symptoms. The effect on laryngeal findings is mixed and patients may experience symptomatic improvement before changes in laryngoscopic appearance.

AB - Background: Patients commonly present with complaints of postnasal drainage (PND) without objective evidence to support a sinonasal or infectious etiology. PND has been attributed to extra-esophageal reflux (EER), and an empiric trial of antireflux medication often is used to treat PND and associated symptoms. This study was performed to (1) evaluate the relationship between symptoms of EER and PND and (2) assess the efficacy of proton pump inhibitors (PPIs) in the management of PND. Methods: Patients with a chief complaint of PND without objective evidence of sinonasal inflammatory disease were enrolled in a prospective, double-blinded, randomized placebo-controlled trial using rabeprazole, 20 mg, orally twice daily or placebo for 90 days. Subjects completed two-site 24-hour pharyngeal pH probe monitoring before treatment. Outcome measures included pre- and posttreatment visual analog scales for PND symptoms, reflux symptom index, and reflux finding score (RFS). Results: Forty-seven patients were enrolled (mean age, 55 years) - 21 patients in the PPI group and 26 in the placebo group. Fifty-six percent of subjects had pH probe confirmed EER using a cutoff of pH <5.0. Baseline symptom measures between subjects with and without EER were not different. Compared with placebo, subjects receiving rabeprazole reported significant reduction in PND frequency (p = 0.0180), hoarseness (p = 0.0164), and chronic cough (p = 0.0204). The RFS decreased slightly in the placebo group (p = 0.1490) whereas it increased slightly in the PPI group (p = 0.5235). This difference between groups was significant (p = 0.0272). Conclusion: Although 50% of subjects had evidence of EER, there was no difference in baseline symptoms between subjects with and without. Our findings support the potential benefit of PPI therapy for reducing PND frequency, hoarseness, and chronic cough, and confirm a placebo effect for other laryngopharyngeal reflux symptoms. The effect on laryngeal findings is mixed and patients may experience symptomatic improvement before changes in laryngoscopic appearance.

KW - Extra-esophageal reflux

KW - Gastro-esophageal reflux

KW - Pepsin

KW - Postnasal drip

KW - Proton pump inhibitors

KW - Reflux

KW - Reflux finding score

KW - Reflux symptom index

UR - http://www.scopus.com/inward/record.url?scp=38349033322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349033322&partnerID=8YFLogxK

U2 - 10.2500/ajr.2007.21.3098

DO - 10.2500/ajr.2007.21.3098

M3 - Article

C2 - 18201449

AN - SCOPUS:38349033322

VL - 21

SP - 695

EP - 701

JO - American Journal of Rhinology and Allergy

JF - American Journal of Rhinology and Allergy

SN - 1945-8924

IS - 6

ER -